This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
by Zacks Equity Research
The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio
by Nalak Das
Five mid-cap stocks have strong revenues and earnings growth potential for 2025. These are: EAT, MAT, CENX, SKYW, ANIP.
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
by Zacks Equity Research
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think ANI (ANIP) Could Surge 26.83%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for ANI (ANIP) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Elevation Oncology Plunges 42% on Ending Development of Lead Drug
by Zacks Equity Research
ELEV decides to stop developing its lead drug after disappointing data from an early-stage study evaluating its sole clinical-stage drug in gastric cancers.
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
by Zacks Equity Research
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corcept Therapeutics (CORT) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
by Zacks Equity Research
Despite the reported death, Sarepta maintains that its gene therapy has a favorable 'benefit-risk profile.'
Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure.
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis Study
by Zacks Equity Research
New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with generalized myasthenia gravis.
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
by Zacks Equity Research
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.
Relative Price Strength: A Smart Strategy Amid Market Turmoil
by Nilanjan Choudhury
OOMA, ANIP, MATX, VIRT and EVER are five stocks with explosive relative price strength.
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
by Zacks Equity Research
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
Zacks.com featured highlights include ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone
by Zacks Equity Research
ANI Pharmaceuticals, Dana, Pitney Bowes, Priority Technology and Kingstone are part of the Zacks Screen of the Week article.
5 High Earnings Yield Value Stocks Amid Renewed Recession Fears
by Rimmi Singhi
Unlock your portfolio value with these high earnings yield value picks like ANIP, DAN, PBI, PRTH and KINS.
Here's Why Ensign Group Can be a Smart Addition to Your Portfolio
by Zacks Equity Research
ENSG remains well-poised for growth on growing service revenues, an expanding healthcare portfolio and sufficient cash balance.
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
Wall Street Analysts Believe ANI (ANIP) Could Rally 32.4%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for ANI (ANIP) points to a 32.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
ANI (ANIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
by Zacks Equity Research
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.